ATE229513T1 - Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen - Google Patents

Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen

Info

Publication number
ATE229513T1
ATE229513T1 AT98402155T AT98402155T ATE229513T1 AT E229513 T1 ATE229513 T1 AT E229513T1 AT 98402155 T AT98402155 T AT 98402155T AT 98402155 T AT98402155 T AT 98402155T AT E229513 T1 ATE229513 T1 AT E229513T1
Authority
AT
Austria
Prior art keywords
hexahydro
napht
oxazine
production
pharmaceutical compositions
Prior art date
Application number
AT98402155T
Other languages
English (en)
Inventor
Jean-Louis Peglion
Jean-Christophe Harmange
Mark Millan
Francoise Lejeune
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE229513T1 publication Critical patent/ATE229513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98402155T 1997-09-01 1998-09-01 Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen ATE229513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710852A FR2767825A1 (fr) 1997-09-01 1997-09-01 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE229513T1 true ATE229513T1 (de) 2002-12-15

Family

ID=9510643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98402155T ATE229513T1 (de) 1997-09-01 1998-09-01 Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen

Country Status (19)

Country Link
US (1) US6025356A (de)
EP (1) EP0899267B1 (de)
JP (1) JP4417451B2 (de)
CN (1) CN1088064C (de)
AT (1) ATE229513T1 (de)
AU (1) AU740928C (de)
BR (1) BR9803933A (de)
CA (1) CA2246482C (de)
DE (1) DE69810034T2 (de)
DK (1) DK0899267T3 (de)
ES (1) ES2189108T3 (de)
FR (1) FR2767825A1 (de)
HK (1) HK1020340A1 (de)
HU (1) HU226059B1 (de)
NO (1) NO311218B1 (de)
NZ (1) NZ331637A (de)
PL (1) PL194533B1 (de)
PT (1) PT899267E (de)
ZA (1) ZA987963B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1534679A4 (de) * 2002-08-30 2007-06-06 Biostratum Inc Inhibitoren von post-amadori advanced glycation endproducts
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
FR2906249B1 (fr) * 2006-09-26 2008-12-19 Servier Lab Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2098511A1 (de) 2008-03-07 2009-09-09 Solvias AG Verfahren zur Herstellung von Verbindungen mit einer Hydronaphtalinstruktur mit einem asymmetrisch substituierten Benzolring
CN102131790A (zh) * 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
WO1991019719A1 (en) * 1990-06-15 1991-12-26 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics

Also Published As

Publication number Publication date
CN1088064C (zh) 2002-07-24
HU226059B1 (en) 2008-04-28
NO984007L (no) 1999-03-02
FR2767825A1 (fr) 1999-02-26
DE69810034T2 (de) 2003-08-14
JPH11130759A (ja) 1999-05-18
HK1020340A1 (en) 2000-04-14
PL194533B1 (pl) 2007-06-29
ZA987963B (en) 1999-03-04
AU8302498A (en) 1999-03-11
PT899267E (pt) 2003-04-30
HU9801951D0 (en) 1998-11-30
AU740928C (en) 2002-05-16
CA2246482C (fr) 2002-11-26
EP0899267A1 (de) 1999-03-03
NZ331637A (en) 1999-07-29
EP0899267B1 (de) 2002-12-11
NO984007D0 (no) 1998-08-31
PL328285A1 (en) 1999-03-15
DK0899267T3 (da) 2003-03-10
US6025356A (en) 2000-02-15
CA2246482A1 (fr) 1999-03-01
HUP9801951A2 (hu) 2000-02-28
ES2189108T3 (es) 2003-07-01
AU740928B2 (en) 2001-11-15
NO311218B1 (no) 2001-10-29
DE69810034D1 (de) 2003-01-23
JP4417451B2 (ja) 2010-02-17
BR9803933A (pt) 2001-04-24
HUP9801951A3 (en) 2000-04-28
CN1222516A (zh) 1999-07-14

Similar Documents

Publication Publication Date Title
DE69426331T2 (de) Arzneimittel gegen nervöse erkrankungen
AU2464997A (en) New 3-(piperid-4-YL)-1,2-benzisoxazole and 3-piperazin-4-YL)-1,2-benzisoxazole compounds, processes for their preparation and pharmaceutical compositions containing them
ATE229513T1 (de) Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen
DK0769296T3 (da) Anvendelse af et natrium- eller lysiniumsalt af crotonsyreamidderivater til fremstilling af et lægemiddel til behandling af cancer
GR3031051T3 (en) Derivatives of indole, indazole and benzisoxazole for the treatment of schizophrenia
ATE281452T1 (de) 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
NO955103D0 (no) Anvendelse av 1,2-broholdige 1,4-dihydropyridiner som legemiddel
ATE198752T1 (de) Tetrazyclisch 1,4-oxazinverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE281453T1 (de) 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0899267

Country of ref document: EP